The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational corporation in Mesa, Arizona (EIN 42-2857240). We publish peer-reviewed medical research, deliver expert-level surgical education, and serve as a site for FDA clinical trials in women’s health.
Mission
The Institute exists to make gynecologic surgery less invasive, better evidenced and more widely available. We pursue that through three activities: producing rigorous systematic reviews and meta-analyses that answer questions surgeons actually face; training surgeons through an accredited fellowship and simulation programme; and developing and evaluating surgical techniques and instrumentation that reduce incision size, pain, recovery time and complications.
Our founding commitment is that these advances should reach all women, regardless of nationality, economic class or ability to pay.
Non-Profit Status
The Marchand Institute for Minimally Invasive Surgery is a not-for-profit research and educational corporation based in Mesa, Arizona, and is recognised by the United States Internal Revenue Service as exempt from federal income tax under Internal Revenue Code section 501(c)(3).
| Legal name | Marchand Institute for Minimally Invasive Surgery |
| Employer Identification Number (EIN) | 42-2857240 |
| Exempt status | Exempt from federal income tax under IRC section 501(c)(3) |
| IRS classification | Private foundation within the meaning of IRC section 509(a) |
| Effective date of exemption | 29 May 2026 |
| Annual return filed | IRS Form 990-PF (Return of Private Foundation), filed annually |
| Accounting period ends | 31 December |
| Registered address | 10238 E. Hampton Ave., Suite 212, Mesa, Arizona 85209, USA |
Contributions to the Institute are deductible by donors under IRC section 170, and the Institute is qualified to receive tax-deductible bequests, devises, transfers and gifts under sections 2055, 2106 and 2522. Journalists, editors and grant administrators can confirm all of the above independently through the IRS Tax Exempt Organization Search using the EIN above.
We are organised and operated exclusively for scientific and educational purposes within the meaning of section 501(c)(3). No part of the Institute’s net earnings inures to the benefit of any private shareholder or individual. Surplus from any activity is applied to the Institute’s research and educational programmes. A copy of the IRS determination letter is available to media and prospective collaborators on request.
Funding and Independence
The Marchand Institute accepts no outside funding for its research programme.
Our systematic reviews and meta-analyses are not supported by pharmaceutical companies, medical device manufacturers, professional societies, advocacy organizations or any other external sponsor. Neither the Institute nor its investigators hold consulting agreements, advisory board fees, speaking fees, equity positions or royalty arrangements with pharmaceutical or medical device companies. Dr. Marchand openly declares no conflicts of interest.
Because there is no sponsor, there is no sponsor influence. No outside party selects our research questions, defines our comparators, reviews our manuscripts before submission, or has any right of approval over what we publish. We publish null results and results unfavourable to popular or commercially promoted techniques, and we have done so repeatedly.
The Institute’s only institutional affiliations are with the participating hospitals of its fellowship programme. Where the Institute participates as a clinical trial site, that work is compensated at fair market value for clinical services performed under a sponsor’s protocol; it is separate from, and does not fund, our research programme.
We do not solicit public donations. If that changes, it will be stated plainly on this page.
Preferred Affiliation Statement
To keep our output correctly aggregated in PubMed, Scopus and Web of Science, authors publishing work performed at or with the Institute should use the following affiliation string exactly.
Marchand Institute for Minimally Invasive Surgery, Mesa, Arizona, USA
Where a journal requires a full postal affiliation:
Marchand Institute for Minimally Invasive Surgery, 10238 E. Hampton Ave., Suite 212, Mesa, AZ 85209, USA
Fellows and trainees should additionally list:
Fellowship in Minimally Invasive and Robotic Gynecologic Surgery, HonorHealth Four Peaks Medical Center, Mesa, AZ, USA
Please do not use shortened or alternative forms such as “Marchand Institute”, “The Marchand Institute, AZ”, “Marchand OBGYN” or “Marchand Institute of Minimally Invasive Surgery” (note: for, not of). Inconsistent strings fragment our indexed record and undercount institutional output. Systematic review protocols should be registered with PROSPERO under the same organizational name.
Researcher Identifiers
Persistent identifiers for the Institute’s director and principal investigator, Greg J. Marchand, MD, FACS, FACOG, FICS:
| ORCID iD | 0000-0003-4724-9148 |
|---|---|
| Google Scholar | Gregory Marchand — Google Scholar profile (verified email at marchandinstitute.org) |
| Scopus Author ID | 57216591264 |
| Web of Science ResearcherID | AAG-7878-2021 |
| ResearchGate | Greg Marchand — ResearchGate profile |
| SciProfiles (MDPI) | 2533203 |
| PubMed collection | All indexed Marchand Institute work in PubMed |
| PROSPERO | 65 systematic review protocols registered under the Institute; 41 with Dr. Marchand as named contact. Search the PROSPERO register. |
| Institute publication database | All 137 works with DOI and PMID · RSS feed |
Dr. Marchand is a verified peer reviewer through the Web of Science Reviewer Recognition Service and ORCID, and an NIH Early Stage Investigator.
Research Impact
| Citations | 1,200+ (Google Scholar); 702 (Scopus); 641 (Web of Science Core Collection) |
|---|---|
| h-index | 18 (Google Scholar); 15 (Scopus); 15 (Web of Science) |
| i10-index | 26 (Google Scholar) |
| Indexed documents | 137 total; 97 peer-reviewed articles |
| Most cited work | Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis. JAMA Network Open. 2022;5(1):e2145653 |
| Second most cited | Systematic review and meta-analysis of COVID-19 maternal and neonatal clinical features and pregnancy outcomes. AJOG Global Reports. 2022;2(1):100049 |
Metrics verified August 2026.
Where to Find Us This Year
- AAGL 2026 Global Congress — 55th Global Congress on Minimally Invasive Gynecologic Surgery, Boston, Massachusetts, November 13–16, 2026. Presenting on surgical treatment of adnexal masses in pediatric patients, and on miniature laparoscopy versus single-port laparoscopy in hysterectomy.
- SLS Minimally Invasive Surgery Week 2026 (MISWeek) — DoubleTree by Hilton at the Entrance to Universal Orlando, Orlando, Florida, December 2–5, 2026. Oral presentation of our Bulkamid systematic review for female stress urinary incontinence on December 3, 2026.
Colleagues, prospective fellows and members of the press are welcome to find us at either meeting. Email maria@marchandobgyn.com to arrange a time.
Contact
Marchand Institute for Minimally Invasive Surgery
10238 E. Hampton Ave., Suite 212, Mesa, Arizona 85209, USA
Telephone (480) 999-0905 · Fax (480) 999-0801
Research and academic enquiries: Propose a Collaboration
Media enquiries: Newsroom and Press Kit